Skip to main content

Table 2 PARP inhibitors in ovarian cancer–G3/G4 Adverse Events

From: Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment

 

OLA (%)

OLA+CED (%)

OLA+CT (%)

VEL (%)

VEL+CHT (%)

NIR (%)

RUC (%)

INI (%)

Nausea

0–8

5

1

1

0

0

3

0

Vomiting

0–4

0

0

0

0

0.5

0

0

Diarrhoea

0–5

23

0

0

0

0

0

8.3

Dehydration

0

0

0

0

0.4

0

0

0

Hyponatremia

0

0

0

0

0.7

0

0

8.3

Abdominal pain

0–8

0

0

0

0

0

1

0

Headache

0

5

1

0

0

0

0

0

Constipation

0–2

0

0

0

0

0

0

0

Decreased appetite

0–2

0

1

0

0

0.5

0

0

Upper abdominal pain

0

0

0

0

0

0

1

0

Arthralgia

0–1

0

0

0

0

0

0

0

Back pain

0–2

0

0

0

0

0

0

0

Asthenia/fatigue

3–11

27

7

0

0

1.5

6

0

Abdominal distension

0–3

0

0

0

0

0

0

0

Leucopenia

0–2

0

5

0.5

0.7

0

0

0

Neutropenia

0–9

0

43

0.5

0.7

1.5

0

0

Lymphopenia

0–4

0

0

0

4.8

0.5

0

8.3

Thrombocytopenia

0

0

6

0.5

0.4

3.5

0

0

Anemia

0–20

0

9

0

0.7

3

0

0

Hypertension

0

41

0

0

0

0

0

8.3

Peripheral sensory neuropathy

2

0

0

0

0

0

0

0

Drug hypersensitivity

0

0

5

0

0

0

0

0

Dyspnea

4

0

0

0

0

0

0

0

Increased AST

0

0

0

0

0

0

0

8.3

Increased ALT

0

0

0

0

0

0

0

16.7

Increased activated partial thromboplastin time

0

0

0

0

0

0

0

8.3

Hyperbilirubinemia

0

0

0

0

0

0

0

8.3

Increased alkaline phosphatase

0

0

0

0

0

0

0

16.7

Increased international normalized ratio

0

0

0

0

0

0

0

16.7

Malignant pleural effusion

0

0

0

0

0

0

0

8.3

Gastro-oesophageal reflux disease

4

0

0

0

0

0

0

0

Death

0

0

0

0

0

0

0

8.3

  1. OLA Olaparib, VEL veliparib, CED cediranib, RUC rucaparib, NIR niraparib, PLA placebo, unk unknown, mt mutated, wt wild type, Pts patients, NR not reported, P Paclitaxel, CBDC Carboplatin, Res platinum resistant, Ref platinum refractory, CT chemotherapy